Nath Bio-Genes (India) Ltd Financials
Company Logo

Nath Bio-Genes (India) Ltd Financial Statement

Nath Bio-Genes (India) Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue32.26
Operating Expense25.63
Net Profit2.89
Net Profit Margin8.96
Earning Per Share1.46
EBIDTA6.63
Effective Tax Rate-0.45

Nath Bio-Genes (India) Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual332.62
Operating Expenses Annual282.24
Operating Profit Annual54.49
Interest Annual9.10
Depreciation1.66
Net Profit Annual40.18
Tax Annual1.95

Nath Bio-Genes (India) Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning37.98
Cash Flow from Operations74.72
Cash Flow from Investing-27.40
Cash Flow from Financing-9.81
Cash Flow at the End75.50

Nath Bio-Genes (India) Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)16.41
PBIT Margin (%)15.43
PBT Margin (%)13.75
Net PROFIT Margin (%)12.08
Return On Networth / Equity (%)6.79
Return On Networth /Employed (%)7.31
Return On Assets (%)5.68
Total Debt / Equity (X)0.18
Asset Turnover Ratio (%)0.47

Nath Bio-Genes (India) Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual249.45
Total Current Assets Annual568.52
Non Current Assets Annual308.57
Total Shareholders Funds Annual610.66
Total Assets Annual877.08

Nath Bio-Genes (India) Ltd Earning Calls

EPS (INR)

Expected

0.58

Reported

0.53

Surprise

-8.62%

Jun 2024

EPS beaten by -8.62%

Mar 2024

EPS beaten by -0.34%

Dec 2023

EPS beaten by 35.51%

Get Your FAQs Right

As of Nov 5, 2024, Nath Bio-Genes (India) Ltd has a market capitalization of 330.19 Cr. Value Research classifies it as a Small-Cap company.
Yes, Nath Bio-Genes (India) Ltd is debt-free with a debt-to-equity ratio of 0.18.
In FY 2023 , Nath Bio-Genes (India) Ltd recorded a total revenue of approximately 332.62 Cr marking a significant milestone in the company's financial performance.
Nath Bio-Genes (India) Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.1% annually, respectively..
Nath Bio-Genes (India) Ltd's current PE ratio is 8.22.
Nath Bio-Genes (India) Ltd's ROCE averaged 6.6% from the FY ending March 2022 to 2024, with a median of 6.8%. It peaked at 7.1% in March 2024, reflecting strong capital efficiency over the period..
Nath Bio-Genes (India) Ltd's latest EBIT is Rs. 51.22 Cr, surpassing the average EBIT of Rs. 15.02 Cr over the 5 years..